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AObjectives: We sought to compare long-term outcomes between percutaneous mitral valvuloplasty and open
heart surgery.
Methods: The study evaluated 402 patients who underwent percutaneous mitral valvuloplasty and 159 patients
who underwent open heart surgery between January 1, 1995, and December 31, 2000. The rates of cardiovascular
death or repeated intervention (redo percutaneous mitral valvuloplasty or open heart surgery) were determined
over a median follow-up of 109 months (mean  SD, 106  27). The therapeutic effects on adverse outcomes
were estimated by the Cox proportional hazards model adjusting differences in the severity of illness before
intervention. The effects of the cardiac rhythm and echocardiographic score were also tested.
Results: The observed (unadjusted) event-free survival was similar for both groups, and the hazard ratio for the
clinical events after percutaneous mitral valvuloplasty as compared with after open heart surgery was 1.510 (95%
confidence interval, 0.914–2.496; P ¼ .1079). However, the adjusted hazard ratio was 3.729 (95% confidence
interval, 1.963–7.082; P< .0001), showing a higher event-free survival in the open heart surgery group. The
adjusted hazard ratio after percutaneous mitral valvuloplasty as compared with after open heart surgery in patients
with echocardiographic scores of 8 or more and atrial fibrillation were 5.348 (95% confidence interval, 2.504–
11.422; P<.001) and 3.440 (95% confidence interval, 1.805–6.555; P ¼ .0002), respectively, whereas the haz-
ard ratio in patients with echocardiographic scores less than 8 and normal sinus rhythm did not show differences.
Conclusions:Open heart surgery was associated with a higher adjusted rate of long-term event-free survival than
percutaneous mitral valvuloplasty. Patients with high echocardiographic scores or atrial fibrillation showed better
outcomes after open heart surgery. (J Thorac Cardiovasc Surg 2010;139:103-10)Percutaneous mitral valvuloplasty (PMV) has been devel-
oped as a logical extension of surgical closed commissurot-
omy for mitral stenosis (MS),1 and excellent hemodynamic
improvement with favorable outcome has been reported by
many investigators.2-11 PMV has rapidly become the initial
treatment of choice for selected patients with MS owing to
benefits such as low early morbidity. As a consequence,
open heart surgery (OHS) including open mitral commis-
surotomy (OMC) and mitral valve replacement (MVR) is
now largely reserved for a minority of patients with a calci-
fied mitral valve or left atrial thrombi. However, most clin-
ical studies report that the mean follow-up duration
associated with excellent clinical outcomes after PMV is
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The Journal of Thoracic and Carience shows that gradual and progressive occurrence of
restenosis with late functional deterioration occurring 5
years after PMV could be a potentially important clinical is-
sue,7 especially when discussing indications for PMV. Fur-
thermore, bileaflet MVR has long been the definitive
aggressive treatment option for patients with MS and shows
greater durability than OMC.12-14 Thus, the efficacy and
long-term outcomes after PMV and OHS need to be reas-
sessed. The present study used observational data to com-
pare long-term outcomes in patients with MS who
underwent PMV or OHS.METHODS
Subjects
The study involved patients who underwent PMV or OHS in our institu-
tion owing to hemodynamically significant MS between January 1, 1995,
and December 31, 2000. Exclusion criteria included prior PMV or OHS,
concomitant significant mitral regurgitation, or aortic valvular or coronary
lesions that required additional aortic valve procedures or coronary artery
bypass grafting. The study group comprised 402 patients who underwent
PMV and 159 patients who underwent OHS. The definite treatment strategy
for patients with MS, PMV or OHS, was determined at the discretion of the
attending cardiologists or referral physicians and was based on echocardio-
graphic score, patient age, and comorbidities, including left atrial thrombi.rdiovascular Surgery c Volume 139, Number 1 103
TABLE 1. Baseline clinical and echocardiographic characteristics
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DOHS (n ¼ 159) PMV (n ¼ 402) P value
Age, y 52  9 44  11 <.001
Female, n (%) 93 (59) 301 (75) <.001
Atrial fibrillation, n (%) 134 (84) 146 (36) <.001
Left atrial AP
diameter, mm
60  10 53  7 <.001
LV systolic
dimension, mm
36  6 33  6 <.001
10Abbreviations and Acronyms
CI ¼ confidence intervals
HR ¼ hazard ratio
MS ¼ mitral stenosis
MVR ¼ mitral valve replacement
OHS ¼ open heart surgery
OMC ¼ open mitral commissurotomy
PMV ¼ percutaneous mitral valvuloplastyLV diastolic
dimension, mm
51  6 49  6 .040
LV ejection
fraction,%
55  9 59  7 <.001
Mitral valve
area, cm2
0.86  0.26 0.95  0.21 <.001
Mean mitral
gradient, mm Hg
13  6 13  6 .667
MR grade 0.8  0.8 0.6  0.6 .001
TR grade 1.7  1.1 1.4  0.9 .001
Peak velocity
of TR, m/s
3.1  0.7 2.9  0.6 .013
Echocardiographic score
Leaflet mobility 2.1  0.5 1.6  0.5 <.001
Leaflet thickening 2.5  0.6 2.1  0.5 <.001
Subvalvular scarring 2.4  0.6 2.0  0.5 <.001
Calcification 2.6  0.6 1.7  0.7 <.001
Total 9.6  1.9 7.3  1.4 <.001
AP,Anteroposterior; LV, left ventricular;MR,mitral regurgitation; TR, tricuspid regur-
gitation. Continuous variables are expressed as mean  SD.Our institutional review board approved the retrospective analysis of the
clinical data of these subjects.
PMV
Cardiac catheterization confirmed severe MS without significant mitral
regurgitation. Experienced physicians then performed PMV using the In-
oue balloon technique while monitoring the conventional hemodynamic
parameters.
OHS
Conventional normothermic cardiopulmonary bypass was performed
with bicaval and ascending aortic cannulation. Myocardial protection
was achieved with antegrade and retrograde tepid blood cardioplegia.
MVR or OMC was performed at the surgeons’ discretion, largely on
the basis of the morphologic features of the rheumatic involvement of
the mitral apparatus. OMC was performed by opening the fused com-
missures using sharp and blunt dissection to create a wide mitral valve
orifice. MVR was performed using the interrupted suture technique with
St Jude Medical (St Jude Medical, Inc, St Paul, Minn) (101 patients)
and Mira (19 patients), Tekna (10 patients), or Carpentier–Edwards
(10 patients) prostheses (all Edwards Lifesciences, Irvine, Calif).
Some patients also underwent tricuspid valve repair with or without
the maze procedure.
Echocardiographic Evaluation
Comprehensive 2-dimensional and color Doppler echocardiographic
evaluation was performed in all patients before PMV or OHS with a Hew-
lett–Packard Sonos 2500 or 5500 imaging system (Hewlett–Packard Com-
pany, Palo Alto, Calif) equipped with a 2.5-MHz transducer. Besides
routine measurements of cardiac chamber dimensions and ejection fraction
by the modified Simpson method, the mitral gradient and the peak pressure
gradient of tricuspid regurgitation were calculated. The morphologic fea-
tures of the mitral valve were categorized as previously described, and the
total echocardiographic score was obtained by adding the scores of each
of the following individual morphologic features: leaflet mobility, thick-
ness, calcification, and subvalvular lesions.15 The mitral valve area was
measured by direct planimetry at the parasternal short-axis view, and the
continuous wave Doppler technique was used to calculate the mitral gradi-
ent and the peak pressure gradient of tricuspid regurgitation. Mitral and tri-
cuspid regurgitation were graded from 0 to 4þ, depending on the spatial
extent of the color flow jet area expressed as a percentage of the left or right
atrial area.
Follow-up
Clinical follow-up was performed 2 and 6 months after PMV or
OHS and yearly thereafter until December 2006. Clinical data were col-
lected either during patient visits to the outpatient clinic or by telephone
interviews. The primary end points were defined as the clinical events
of cardiovascular death and redo PMV or OHS. The National Vital
Statistics death file was used to confirm mortality during follow-up.4 The Journal of Thoracic and Cardiovascular SurgA nationwide survey was done to confirm redo PMV or OHS using
cardiac surgery and percutaneous intervention reporting system. If a pa-
tient in the PMV group underwent OHS during follow-up, the patient
was censored at the time of reoperation. Median follow-up duration
was 109 months (mean  SD, 106  27).
Data Analysis
Categorical variables are presented as numbers and percentages and were
compared by c2 or Fisher’s exact test. Continuous variables are presented as
mean  SD and were compared by the unpaired Student t tests.
The Cox proportional hazards model was used to determine whether the
long-term event-free survival differed significantly between PMV and OHS
patients after controlling for the differences in preprocedural risk profiles.
Also, Cox proportional hazards regression was used to determine whether
there were treatment-related differences in the long-term event-free survival
among patients with high total echocardiographic scores (8) and those
with atrial fibrillation. Multivariable analyses (Cox proportional hazards re-
gression) involved a backward elimination technique, and only variables
with a P value of less than .10 were used in the final model. The proportional
hazards assumption was confirmed through examination of log (log [sur-
vival]) curves and testing of partial (Schoenfeld) residuals,16 and no relevant
violations were found.
Additionally, a propensity score analysis was carried out to determine the
causal effect of the group on the long-term event-free survival. The propen-
sity scores were estimated by multiple logistic regression analysis without
regard to outcome variables. A full nonparsimonious model was developed
including all variables presented in Table 1. This model yielded a c-statistic
of 0.911, and a Hosmer–Lemeshow goodness-of-fit test P value of .2338 in-
dicating a strong ability to differentiate between patients undergoing PMV
and those undergoing OHS. The individual propensity score was incorpo-
rated into Cox proportional hazards models as a covariate to calculate theery c January 2010
TABLE 2. Summary of clinical events
OHS (n ¼ 159) PMV (n ¼ 402)
Cardiovascular death,* n (%) 17 (11%) 18 (5%)
Congestive heart failure, n 3 6
Cerebrovascular accident, n 1 5
Sudden death, n 4 1
Operative mortality, n (initial/redo) 4 (3/1) 2 (1/1)
Acute myocardial infarction, n 1 1
Subacute bacterial endocarditis, n 4 3
Noncardiovascular death
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was subdivided into quintiles. Usually, propensity score matching is mostly
preferred in the aspect of reducing bias and mean squared error. However, it
is necessary that the two treatment groups overlap well enough in terms of
the propensity scores for sound analysis. However, in our study, the two
treatment groups do not overlap well enough in terms of the propensity
scores. Thus, we chose alternative methods (stratification and regression
adjustment) for final analysis. Treatment effects were separately estimated
within each quintile and then quintile estimates were combined to measure
an overall estimate of the treatment effect using a stratified Cox regression
model. All analyses were conducted with SAS software (version 8.2; SAS
Institute, Inc, Cary, NC).
Malignancy, n 5 5
Accident/trauma, n 1 2
Suicide, n 1 0
Liver disease, n 1 1
Chronic renal failure, n 0 1
Repeated Intervention,y n (%) 4 (3%) 61 (15%)
OHS, n 4 51
Redo PMV, n 0 10
OHS, Open heart surgery; PMV, percutaneous mitral valvuloplasty. *P ¼ .009;
yP< .001.RESULTS
Baseline Characteristics and Immediate Outcomes
The study involved a total of 561 patients, comprising 402
PMV patients and 159 OHS patients. Of the OHS patients,
19 (12%) underwent OMC and the remaining 140 under-
went MVR. Concomitant tricuspid valve repair and maze
procedures were performed in 38 (24%) and 26 (16%)
OHS patients, respectively. Baseline clinical and echocar-
diographic characteristics for all patients are summarized
in Table 1. OHS patient characteristics included a higher
mean age, a prevalence of male sex, atrial fibrillation with
a larger left atrium, lower left ventricular ejection fraction,
smaller mitral valve area, and higher pulmonary artery pres-
sure and echocardiographic scores. In the PMV group, 1 pa-
tient underwent emergency MVR immediately after PMV
owing to the development of severe mitral regurgitation,
but subsequently died. The surgical mortality was 2% (3/
159) in the OHS group.Follow-up Data
The median follow-up was 97 months in the OHS group
and 112 months in the PMV group. The echocardiographic
data at last follow-up showed lower mean mitral gradient
(4.1  2.1 vs 6.8  3.5 mm Hg; P<.001) and peak pulmo-
nary artery pressure (25  2 vs 30  3 mm Hg) in the OHS
group. A total of 52 (9%) patients died during follow-up
(Table 2). The completeness of follow-up was 93%, and
higher mortality in the OHS group (16% vs 7%; P ¼
.001) with significantly higher mean age could explain the
observed difference of the median follow-up between the
groups. Cardiovascular death comprised greater than two
thirds of total deaths in both the PMV (18/27) and OHS
(17/25) groups. In the OHS group, 1 patient had prosthesis
thrombosis and underwent emergency redo OHS, but subse-
quently died. Another patient underwent a redo MVR owing
to infective endocarditis. In 2 patients, redo OHS for tricus-
pid valve replacement was required to control severe tricus-
pid regurgitation 64 and 72 months after initial MVR,
respectively. In the PMV group, 51 patients underwent sub-
sequent OHS and 10 patients redo PMV.
The observed unadjusted 5-year cardiovascular death–
free survival was 0.950 (95% confidence interval [CI],The Journal of Thoracic and Ca0.917–0.983) in the OHS group and 0.978 (95% CI,
0.964–0.992) in the PMV group. The HR after PMV as com-
pared with after OHS was 0.367 (95%CI, 0.188–0.711; P¼
.003). However, after adjusting for age, gender, left atrial
anteroposterior diameter, and echocardiographic score, the
HR was 1.328 (95% CI, 0.542–3.257; P¼ .5352). Both un-
adjusted and adjusted cardiovascular death–free survival
curves are presented in Figure 1 (adjusted Cox model for
propensity score). For the unadjusted Kaplan–Meier sur-
vival curve, the survival was significantly higher after
PMV than after OHS (P¼ .0002), whereas there was no sig-
nificant difference after adjustment (P ¼ .6887). The ad-
justed probability of cardiovascular death–free survival in
the OHS groups was 98%  1% at 5 years, 97%  1%
at 7 years, and 96%  2% at 9 years; in the PMV group
it was 98%  1% at 5 years, 96%  1% at 7 years, and
95%  2% at 9 years.
The primary end point of the present study was the fre-
quency of hard clinical events including cardiovascular
death, redo PMV, and OHS. This frequency was found to
be 13% (20/159) in the OHS group and 19% (78/402) in
the PMV group (P ¼ .055). Redo was more frequent in
the PMV group (15% vs 2%; P< .001). The observed
(unadjusted) event-free survival was similar for both the
PMV and OHS groups, and the HR after PMV as compared
with after OHS was 1.510 (95% CI, 0.914–2.496; P ¼
.1079; Table 3). However, after adjusting for age, left atrial
anteroposterior diameter, and echocardiographic score, the
HR was 3.729 (95% CI, 1.962–7.082; P< .0011), and
this trend of a lower event-free survival in the PMV group
was confirmed again after adjustment with the propensity
score. Both unadjusted and adjusted event-free survival
curves are shown in Figure 1 (adjusted Cox model for pro-
pensity score). Unadjusted Kaplan–Meier survival curverdiovascular Surgery c Volume 139, Number 1 105
FIGURE 1. Kaplan–Meier analysis. Unadjusted survival (A) and event-free survival (C). Adjusted survival (B) and event-free survival (D).OHS,Open heart
surgery; PMV, percutaneous mitral valvuloplasty.
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in terms of event-free survival between groups (P ¼ .1051),
whereas the survival was higher after OHS than after PMV
in the adjusted analysis (P< .0001). The adjusted probabil-
ity of clinical event-free survival for the OHS groups was
98%  1% at 3 years, 97%  1% at 5 years, 95% 
TABLE 3. Hazard ratios for clinical events (cardiovascular death or
repeated intervention) for PMV compared with OHS
Analytical approach Hazard ratios 95% CI P value
A. The original sample
Unadjusted 1.510 0.914–2.496 .1079







Stratum Q1 — — —
Q2 1.689 0.225–12.661 .6098
Q3 1.047 0.241–4.540 .9516
Q4 3.444 1.310–9.055 .0121
Q5 2.927 1.211–7.075 .0171
Summaryy 2.687 1.491–4.842 .0010
PMV, Percutaneous mitral valvuloplasty; OHS, open heart surgery; CI, confidence
intervals. *Adjusting variables: age, left atrial size, and echocardiographic score.
yHomogeneous test P value ¼ .563.
106 The Journal of Thoracic and Cardiovascular Surg1% at 7 years, and 94%  1% at 9 years; for the PMV
group it was 93%  1% at 3 years, 90%  1% at 5 years,
83%  1% at 7 years, and 80%  2% at 9 years.Effects of Echocardiographic Score and Rhythm
Event-free survival for both OHS and PMV groups
according to the echocardiographic score is illustrated in
Figure 2. Patients with echocardiographic scores of 8 or
more showed lower event-free survivals after PMV, whereas
the echocardiographic score was not associated with event-
free survival after OHS. The adjusted HR for the clinical
events after PMV as compared with after OHS in patients
with echocardiographic scores of 8 or more was 5.348
(95% CI, 2.504–11.422; P< .001), whereas the HR in
patients with echocardiographic scores less than 8 was
1.432 (95% CI, 0.533–5.850; P ¼ .4767).
Before intervention, atrial fibrillation was significantly
more prevalent in the OHS group (84% vs 36%; P <
.001). During follow-up, this prevalence decreased from
84% to 64% (102/159) in the OHS group and increased
from 36% to 53% (215/402) in the PMV group. Conversion
of cardiac rhythm from normal sinus rhythm to atrial fibril-
lation was more frequently observed in the PMV group
(17% [70/402] vs 4% [6/159]; P<.001). Conversely, spon-
taneous sinus rhythm conversion from atrial fibrillationery c January 2010
FIGURE 2. Kaplan–Meier event-free survival curves according to echocardiographic scores (A and B) and cardiac rhythm (C and D) after open heart surgery
(OHS, A and C) or percutaneous mitral valvuloplasty (PMV, B and D). A-FIB, Atrial fibrillation.
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vs 1% [2/402]; P < .001). The effect of initial cardiac
rhythm on event-free survival in the OHS and PMV groups
is shown in Figure 2. Although patients with atrial fibrilla-
tion showed lower event-free survivals after PMV, there
was no such association between cardiac rhythm and
event-free survival in the OHS group. The adjusted HR after
PMV as compared with after OHS in patients with normal
sinus rhythm was 2.138 (95% CI, 0.620–7.368; P ¼
.2288), whereas the HR in patients with atrial fibrillation
was 3.440 (95% CI, 1.805–6.555; P ¼ .0002). Thus,
patients with an echocardiographic score of 8 or more or
with atrial fibrillation showed significantly lower event-
free survivals after PMV than after OHS (Figure 3).
DISCUSSION
The present observational study found that although the
adjusted long-term risk of cardiovascular death was similar
for both PMV and OHS, the adjusted long-term risk of
hard clinical events (including cardiovascular death and
redo PMV or repeated OHS) was higher for PMV. Also,
both high echocardiographic score (8) and atrial fibrilla-
tion were associated with lower event-free survivals after
PMV, but not after OHS, suggesting that these clinical vari-The Journal of Thoracic and Caables should be seriously considered when choosing treat-
ments for patients with MS.
Early randomized, controlled studies showed similar clin-
ical outcomes for both PMV and surgical techniques.17-19
This finding may have been largely due to the studies having
insufficient statistical power. Such trials involved small
numbers of patients (<50 for each intervention) and con-
tained selection biases. Those trials only included young
MS patients with a mean age of the mid-to-late twenties.
In one study the mean echocardiographic score was 6 using
the Wilkins scoring system,19 and another trial excluded pa-
tients with atrial fibrillation.17,18 Such selection criteria are
quite different from those used in most current studies in de-
veloped countries, which usually include middle-aged MS
patients with a mean echocardiographic score of 8 and pa-
tients with atrial fibrillation. Given that age and baseline
echocardiographic score representing the mitral valve mor-
phologic features are two important factors for both proce-
dural success and long-term event-free survival,6,7,9,11,20,21
it is unlikely that data from early clinical trials provide
a sound rationale for the current widespread clinical applica-
tion of PMV in older patients with higher echocardiographic
scores or atrial fibrillation. The limitation of previous clini-
cal studies reporting on clinical outcomes after PMV isrdiovascular Surgery c Volume 139, Number 1 107
FIGURE 3. Kaplan–Meier event-free survival curves showing different impact of the treatment option (PMV versus OHS) in patients with mitral stenosis
having an echocardiographic score of 8 or more or atrial fibrillation. OHS, Open heart surgery; PMV, percutaneous mitral valvuloplasty.
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real clinical impact of this intervention, with the duration of
most clinical and echocardiographic outcome studies being
less than 5 years. Gradual deterioration of functional class
and a continued risk of mitral valve surgery after PMV
were identified as challenging issues in both the multicenter
registry and a large single center report.7,11,22 Moreover,
sharp deterioration of functional status is reported to begin
5 years after PMV in patients with relatively favorable mitral
morphologic features.7
OHS including OMC and MVR has a longer history
than PMV as a useful treatment option for patients with
MS. Along with technical advances and successful clinical
introduction of new-generation bileaflet mechanical valves,
the superior durability of MVR over OMC has been widely
accepted and has led to MVR being recommended as the
definitive aggressive treatment option. We found that de-
spite the mean mitral gradient being similar in each group
before intervention, it was lower in the OHS group at fol-
low-up (4.1  2.1 vs 6.8  3.5 mm Hg; P< .001). More-
over, OHS has advantages over PMV in providing the
potential for additional surgical techniques to manage tri-
cuspid regurgitation and atrial fibrillation, which frequently
accompany MS and are important prognostic factors during108 The Journal of Thoracic and Cardiovascular Surglong-term follow-up.23-28 Contradictory results are avail-
able about the impact of atrial fibrillation on short- and
long-term outcome after PMV.2,9,29,30 All previous studies
compared the frequency of development of restenosis or
adverse clinical outcomes including redo PMV, MVR, or
cardiac death in patients with normal sinus rhythm versus
atrial fibrillation; thus, despite higher event rates in patients
with atrial fibrillation than in those with sinus rhythm after
PMV,2,9,30 it has not been known whether OHS is a better
strategy than PMV in patients with MS and atrial fibrilla-
tion. The present study has confirmed that OHS is a very
effective treatment option for MS irrespective of echocar-
diographic score or cardiac rhythm, and these data suggest
that OHS is being underused as the initial intervention in
some patients with MS.
The low early morbidity and comparable immediate
hemodynamic benefits associatedwith PMVhave led it to be-
come the ‘‘gold standard’’ treatment option in patients with
MS, whereas OHS has been reserved for the minority of
patients with MS who have atrial thrombi or unfavorable
mitral valve morphologic features, including heavy calcifica-
tion. Thus, the application of OHS for patients with MS has
significantly declined. However, the variable nature of base-
line clinical characteristics such as age, echocardiographicery c January 2010
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meaning that simple comparisons of event-free survivals or
mortality between PMV and OHS groups is not sufficient
to draw firm conclusions given selection bias. Selection
bias was minimized in the present study by adjusting for dif-
ferences among patients in terms of demographic char-
acteristics, coexisting conditions, and echocardiographic
features including mitral valve morphologic features and he-
modynamic state. Nevertheless, there remains the possibility
that observational studiesmay fail to identify all confounders,
and it is also true that propensity analyses cannot account for
selection bias related to unmeasured characteristics.
The current study was not a randomized, controlled trial
and suffers from significant difference of baseline character-
istics between PMV and OHS groups. Despite unfavorable
conditions in the OHS group, including significantly higher
mean age, echocardiographic score, and higher prevalence
of atrial fibrillation, sophisticated statistical data transforma-
tion demonstrated the superiority of OHS. We believe this
finding supports the necessity of a randomized, controlled
trial with long-term follow-up. In addition, the choice of
treatment was left to the physician in this study, and one
of the treatment options may have been contraindicated in
some patients. Moreover, there are often many consider-
ations when choosing the appropriate intervention for pa-
tients with MS. PMV is far less invasive than OHS and
has a lower early morbidity, resulting in many patients pos-
sibly preferring this option. Further cost–benefit analysis
comparing PMV and OHS is required, particularly taking
into consideration the life expectancy and the relative merits
of short- and long-term risks. Lack of data regarding other
complications, including nonfatal embolic episodes, which
could affect the quality of life, is another limitation of this
study. Less than 20% of patients with atrial fibrillation un-
derwent an antiarrhythmic procedure during OHS in this
study, inasmuch as the maze procedure was not fully estab-
lished in our institution during the study period and there
was a major concern about the efficacy of the maze proce-
dure in patients with rheumatic MS and a large left atrium.
Inasmuch as we have confirmed the superiority of OHS,
evenwithout the additive antiarrhythmic procedure, this lim-
itation does not mitigate the main finding of our study.
In conclusion, as better long-term outcome is anticipated
in patients with echocardiographic scores of 8 or more or
with atrial fibrillation after OHS, careful consideration is
warranted in choosing the appropriate treatment option in
these selected patients.
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